Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.55 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 2/20 | 0.49 |
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8111105 | 0.96 | TLR2 (0.59) | TLR2SLC17A5TNFMDM4TP53 | |
| SCHEMBL10073558 | 0.96 | TLR2 (0.59) | TLR2SLC17A5TNFMDM4TP53 | |
| SCHEMBL4719374 | 0.92 | TLR2 (0.56) | TLR2SLC17A5TNFMDM4TP53 | |
| SCHEMBL16801655 | 0.87 | SLC17A5 (0.54) | TLR2SLC17A5MDM4TP53MDM2 | |
| SCHEMBL20780206 | 0.87 | TLR2 (0.53) | TLR2SLC17A5TNFMDM4TP53 | |
| SCHEMBL22636828 | 0.86 | TLR2 (0.57) | TLR2SLC17A5TNFMDM4TP53 | |
| SCHEMBL22636830 | 0.86 | TLR2 (0.57) | TLR2SLC17A5TNFMDM4TP53 | |
| SCHEMBL18689466 | 0.86 | TLR2 (0.57) | TLR2SLC17A5TNFMDM4TP53 | |
| SCHEMBL22636827 | 0.86 | TLR2 (0.57) | TLR2SLC17A5TNFMDM4TP53 | |
| SCHEMBL18689465 | 0.86 | TLR2 (0.57) | TLR2SLC17A5TNFMDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6251882-B1 | TREATING LEUKEMIA, BREAST CANCER, PROSTATE CANCER, OR BRAIN TUMOR | PARKER HUGHES INSTITUTE | 2001-06-26 | — | — | US | claimed |
| EP-1091934-A2 | ALKYL KETONES AS POTENT ANTI-CANCER AGENTS | Parker Hughes Institute (US) | 2001-04-18 | — | — | EP | claimed |
| WO-2000000469-A2 | ALKYL KETONES AS POTENT ANTI-CANCER AGENTS | PARKER HUGHES INSTITUTE (US) | 2000-01-06 | — | — | WO | claimed |
| US-6251882-B1 | TREATING LEUKEMIA, BREAST CANCER, PROSTATE CANCER, OR BRAIN TUMOR | PARKER HUGHES INSTITUTE | 2001-06-26 | — | — | US | disclosed |
| EP-1091934-A2 | ALKYL KETONES AS POTENT ANTI-CANCER AGENTS | Parker Hughes Institute (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000000469-A2 | ALKYL KETONES AS POTENT ANTI-CANCER AGENTS | PARKER HUGHES INSTITUTE (US) | 2000-01-06 | — | — | WO | disclosed |